• Alias: PR-171
    • Irreversible, epoxomicin-related proteasome inhibitor of the ubiquitin-proteasome pathway that potently binds to and specifically inhibits the chymotrypsin-like 20S proteasome (ChT-L) and immunoproteasome activities leading to cell cycle arrest and apoptosis
    • FDA approved for MM
    • Recommended dose: 20 mg/m2 IV on days 1 and 2 of each week for 3 weeks of a 28-day cycle; may increase dose in subsequent cycles if tolerated to 27 mg/m2 IV on days 1 and 2 of each week for 3 weeks of a 28-day cycle. All dosing on cycle 1 should n and steroids premedication to prevent infusion-related side effects (chills, fevers, myalgia, flushing).
    Other topics in Targeted and Immunotherapy Agents